ERBB2 and breast cancer: Since the approval of trastuzumab for ERBB2-positive tumors in 1998, targeted systemic therapy remains a paramount goal of drug discovery and clinical care for breast cancer treatment.20 PARP inhibitors represent one of the newer classes of targeted therapies for breast and other solid tumors.